

## Ilana Kattan

Counsel

Washington, D.C.

### Biography

As Counsel on the Antitrust, Competition and Economic Regulation team at Hogan Lovells, Ilana Kattan advises companies on the antitrust risks of their transactions and shepherds them through complex and in-depth merger control processes in the United States and abroad.

Ilana also represents companies before the antitrust enforcement agencies, including the U.S. Department of Justice and the Federal Trade Commission, on conduct investigations, and advises companies on a range of antitrust issues, including licensing agreements, joint ventures and other collaborations, and behavioral issues.

Ilana has experience working with companies across a wide range of industries, such as publishing, chemicals, industrials, healthcare, and technology. She has particular experience representing companies in the Life Sciences sector, where she regularly advises pharmaceutical and medical device companies.

Before joining the firm, Ilana was a Special Counsel in the Washington, DC office of a major international law firm. During her time at that firm, Ilana spent six months as part of the London team, where she gained valuable in-depth experience on UK merger control. Ilana was also seconded to a major technology company, where she worked on the company's docket of antitrust litigation and regulatory matters.

Outside of the office, Ilana serves on the board of



### Phone

+1 202 637 5626

### Fax

+1 202 637 5910

### Email

[ilana.kattan@hoganlovells.com](mailto:ilana.kattan@hoganlovells.com)

---

### Practices

Antitrust and Competition

---

### Industries

Life Sciences and Health Care  
Manufacturing and Industrials  
Technology and Telecoms

---

### Areas of focus

Merger Control  
Agency Investigations  
Competition Compliance

---

### Education and admissions

directors of Makom, an organization that supports and empowers individuals with intellectual and developmental disabilities.

## Representative experience

Represented Johnson & Johnson on an ongoing basis, including in its \$6.5bn acquisition of Momenta Pharmaceuticals and its \$30bn acquisition of Actelion Pharmaceuticals\*

Represented Sanderling Renal in the acquisition of renal dialysis clinics divested by DaVita and the University of Utah pursuant to a Federal Trade Commission consent order\*

Represented BioNTech in its collaboration with Pfizer for a COVID-19 vaccine\*

Represented Cengage in its proposed merger of equals with McGraw-Hill\*

Represented Hamakua Energy Partners in litigation alleging an illegal agreement to terminate Hu Honua's power purchase agreement with the power grid operator on the Big Island of Hawaii\*

Represented Rexam in its acquisition by Ball\*

Represented Novartis in its consumer healthcare joint venture with GlaxoSmithKline; part of a complex set of transactions named Matter of the Year by *Global Competition Review*\*

Represented Hachette Group in various litigations and in recent actions against major trade book publishers\*

\*Matter handled prior to joining Hogan Lovells.

## Latest thinking and events

- News
  - FTC seeks to reinvigorate enforcement of Robinson-Patman Act
- Sponsorships and Speaking Engagements
  - GCR Live: Antitrust in Pharmaceuticals
- Hogan Lovells Events

## Education

J.D., Vanderbilt Law School, Order of the Coif, 2012

B.A., Vanderbilt University, Summa Cum Laude, 2009

---

## Memberships

Vice Chair - Technology Committee, American Bar Association's Antitrust Law Section

Special Counsel to the Committee Officer, American Bar Association's Antitrust Law Section

---

## Bar admissions and qualifications

Maryland

District of Columbia

---

- Antitrust-year-in-review and a look forward to 2023
- News
  - FTC expands its interpretation of its Competition Enforcement Mandate
- News
  - DOJ Antitrust Division cracks down on interlocking directorates
- ■ Mind the vertical gap: An update on the new rules on vertical agreements in the EU and UK